Press Releases Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 13/06/2025 BST			5-day change	1st Jan Change
4.510 ^USD	-2.59%		-2.17%	-5.85%

06-12	Vanda Pharmaceuticals Inc., Q1 2025 Earnings Call, May 07, 2025
06-10	Vanda Pharmaceuticals Inc. Announces First Patient Dosed in A Trial Evaluating VCA-894A in Charcot-Marie-Tooth Disease Type 2S	CI

Press Releases

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S	06-10	PR
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025	05-16	PR
Vanda: Q1 Earnings Snapshot	05-07	AQ
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025	05-02	PR
Vanda Pharmaceuticals Inc. v. FDA: Industry's Latest Attempt To Clarify Off-Label Promotion Rules	04-27	AQ
FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA	04-23	PR
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia	03-31	PR
Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"	02-24	PR
Vanda: Q4 Earnings Snapshot	02-13	AQ
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results	02-13	PR
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025	02-05	PR
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis	01-27	PR
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera	12-20	PR
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.	12-17	BU
Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences	11-12	PR
Vanda Pharmaceuticals : Reports Third Quarter 2024 Financial Results Form 8 K	11-06	PU
Vanda: Q3 Earnings Snapshot	11-06	AQ
Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results	11-06	PR
Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA	11-02	PR
Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024	30/10/24	PR
Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA	25/10/24	PR
Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA	18/10/24	PR
Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 per Share	15/10/24	AQ
Vanda Pharmaceuticals : Confirms Receipt of Economically Identical Unsolicited, Non Binding Proposal from Cycle Group Holdings Ltd Form 8 K	15/10/24	PU
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.	14/10/24	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Press Releases

Filters